Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies

OBJECTIVE: To further characterize the effect of guselkumab, a selective IL-23p19-subunit inhibitor approved for PsA, on enthesitis and assess relationships between enthesitis resolution and patient status/outcomes. METHODS: Adults with active PsA despite standard therapies in the phase 3 DISCOVER-1...

Descripción completa

Detalles Bibliográficos
Autores principales: McGonagle, Dennis, McInnes, Iain B, Deodhar, Atul, Schett, Georg, Shawi, May, Kafka, Shelly, Karyekar, Chetan S, Kollmeier, Alexa P, Hsia, Elizabeth C, Xu, Xie L, Sheng, Shihong, Agarwal, Prasheen, Zhou, Bei, Ritchlin, Christopher T, Rahman, Proton, Mease, Philip J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566200/
https://www.ncbi.nlm.nih.gov/pubmed/33822898
http://dx.doi.org/10.1093/rheumatology/keab285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566200/
https://www.ncbi.nlm.nih.gov/pubmed/33822898
http://dx.doi.org/10.1093/rheumatology/keab285

Ejemplares similares